As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...

总部位于马萨诸塞州剑桥的Sage Therapeutics, Inc.宣布，其首席医疗官Laura Gault医学博士将于2025年3月21日离职。该生物制药公司专注于开发治疗中枢神经系统疾病的药物，目前维持着现金多于债务的强健资产负债表。公司周一确认，Gault博士的离职并非由于任何内部分歧，而是为了寻求新的发展机会。

马萨诸塞州剑桥市 - 市值4.49亿美元、专注于脑健康治疗的生物制药公司Sage Therapeutics, Inc. (NASDAQ: SAGE )今日宣布，其首席医疗官Laura Gault博士将离职寻求新的发展机会。她的离职将于2025年3月21日生效。Gault博士自2022年11月加入公司以来，一直负责监督公司的产品管线开发。根据 InvestingPro ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

As it waits for its Alzheimer’s drug verdict, Biogen stumps up $1.5bn-plus upfront for rights to Sage drugs zuranolone for depression and SAGE-324 for essential tremor ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since rejecting Biogen’s unsolicited acquisition offer. Sage Therapeutics Inc.

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $1.3 million in the fourth quarter of 2024 compared to $8.3 million in ...